# Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

> **NCT00293839** · PHASE3 · COMPLETED · sponsor: **Alza Corporation, DE, USA** · enrollment: 790 (actual)

## Conditions studied

- Urinary Incontinence

## Interventions

- **DRUG:** oxybutynin chloride

## Key facts

- **NCT ID:** NCT00293839
- **Lead sponsor:** Alza Corporation, DE, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2002-12
- **Target enrollment:** 790 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293839, "Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00293839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*